Abstract
Abstract
Purpose
We aimed to estimate health state utility values (HSUVs) for the key health states found in opioid use disorder (OUD) cost-effectiveness models in the published literature.
Methods
Data obtained from six trials representing 1,777 individuals with OUD. We implemented mapping algorithms to harmonize data from different measures of quality of life (the SF-12 Versions 1 and 2 and the EQ-5D-3 L). We performed a regression analysis to quantify the relationship between HSUVs and the following variables: days of extra-medical opioid use in the past 30 days, injecting behaviors, treatment with medications for OUD, HIV status, and age. A secondary analysis explored the impact of opioid withdrawal symptoms.
Results
There were statistically significant reductions in HSUVs associated with extra-medical opioid use (-0.002 (95% CI [-0.003,-0.0001]) to -0.003 (95% CI [-0.005,-0.002]) per additional day of heroin or other opiate use, respectively), drug injecting compared to not injecting (-0.043 (95% CI [-0.079,-0.006])), HIV-positive diagnosis compared to no diagnosis (-0.074 (95% CI [-0.143,-0.005])), and age (-0.001 per year (95% CI [-0.003,-0.0002])). Parameters associated with medications for OUD treatment were not statistically significant after controlling for extra-medical opioid use (0.0131 (95% CI [-0.0479,0.0769])), in line with prior studies. The secondary analysis revealed that withdrawal symptoms are a fundamental driver of HSUVs, with predictions of 0.817 (95% CI [0.768, 0.858]), 0.705 (95% CI [0.607, 0.786]), and 0.367 (95% CI [0.180, 0.575]) for moderate, severe, and worst level of symptoms, respectively.
Conclusion
We observed HSUVs for OUD that were higher than those from previous studies that had been conducted without input from people living with the condition.
Funder
National Institute on Drug Abuse
National Institute of Allergy and Infectious Diseases/National Institute on Drug Abuse
Publisher
Springer Science and Business Media LLC
Reference78 articles.
1. National Center for Health Statistics (2021). Products-vital statistics rapid release-provisional drug overdose data. Centers for Disease Control and Prevention. Retrieved from https://www.cdc.gov/nchs/nvss/vsrr/drug-overdose-data.htm#dashboard
2. Patton, T., Revill, P., Sculpher, M., & Borquez, A. (2022). Using economic evaluation to inform responses to the opioid epidemic in the United States: Challenges and suggestions for Future Research. Substance use & Misuse, 57(5), 815–821.
3. Briggs, A., Sculpher, M., & Claxton, K. (2006). Decision modelling for health economic evaluation. Oup Oxford.
4. Wolowacz, S. E., Briggs, A., Belozeroff, V., Clarke, P., Doward, L., Goeree, R., … Norman, R. (2016). Estimating health-state utility for economic models in clinical studies: an ISPOR good research practices task force report. Value in Health, 19(6), 704–719.
5. Barbosa, C., Dowd, W. N., & Zarkin, G. (2020). Economic evaluation of interventions to address opioid misuse: A systematic review of methods used in simulation modeling studies. Value in Health, 23(8), 1096–1108.